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Abstract
Background—Findings from clinical trials and population-based studies have differed as to 
whether mortality within 30 days of diagnosis (early death) of acute promyelocytic leukemia has 
decreased in the era of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy.
Methods—We investigated 7- and 30-day mortality and survival in 772 patients aged 0–39 years 
when diagnosed with APL during 1988–2011, using data from the California Cancer Registry. We 
used logistic regression and Cox proportional models to examine the association of early death 
and survival, respectively, with sociodemographic and clinical factors.
Results—Overall 30-day mortality decreased significantly over time, from 26% (1988–1995) to 
14% (2004–2011) (P=0.004). In multivariable analysis, the odds of 30-day mortality were 3 times 
as high during 1988–1995 than 2004–2011 (P=0.001). However, 7-day mortality did not improve 
over time (P=0.229). When patients who died within 7 days of diagnosis were excluded, 30-day 
mortality during 1996–2011 was 3%–8%, similar to levels reported in clinical trials. Higher early 
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death and lower survival were associated with lack of health insurance (1996–2011) (early death 
OR=2.67, P=0.031) and Hispanic race/ethnicity (early death OR=2.13, P=0.014). Early death was 
not associated with age, sex, socioeconomic status or hospital type. Black patients also 
experienced worse survival.
Conclusions—Our findings revealed a decreased 30-day mortality during the ATRA era, but 7-
day mortality remained high. Efforts to achieve equal outcomes in young patients with APL 
should focus on improving access to effective treatment, mainly among uninsured patients and 
those of Hispanic and Black race/ethnicity.
Keywords
acute promyelocytic leukemia; ATRA; early death; survival; children; adolescents; young adults; 
health insurance; health disparities
INTRODUCTION
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that 
carries the PML/RAR-α fusion in more than 90% of cases. Bleeding and thrombosis are 
frequent and can be aggravated by cytotoxic chemotherapy, resulting in early death due 
mainly to intracranial hemorrhage.1
An estimated 600–800 new cases of APL (4%–13% of AML cases) occur annually in the 
U.S., most frequently in adults.2, 3 While APL was once highly fatal, the addition of all-
trans retinoic acid (ATRA) to anthracycline-based chemotherapy and the introduction of 
arsenic trioxide (arsenic) have dramatically improved outcomes; currently, 95%–100% of 
patients with APL gain complete remission.4, 5 Moreover, arsenic has become the treatment 
of choice for relapsed APL after frontline treatment with ATRA and chemotherapy.6
ATRA and arsenic rapidly reduce the risk of hemorrhage and should be initiated as soon as 
APL is suspected.7 ATRA was approved by the U.S. Food and Drug Administration (FDA) 
in November, 1995 and arsenic in September, 2000. During the ATRA era, early death has 
decreased overall, from approximately 20%8, 9 to 5%–10%.10 However, early death remains 
high in the U.S.11, 12 and Europe,13 implicating factors other than ATRA.
Because recent studies have examined early death and survival in patients aged ≥15 
years11, 13, 14 and there are few reports of population-based studies in young patients with 
APL (Supplementary Table S1), we investigated early death and survival in patients in 
California, diagnosed at ages 0–39 years over a 25-year period, and assessed the association 
of sociodemographic and clinical factors with these outcomes.
PATIENTS AND METHODS
Patient selection
Data were obtained from the California Cancer Registry, to which reporting is mandatory 
and completeness of cases is at least 98%.15 We identified all patients with a first, primary 
APL diagnosed at age 0 to 39 years during 1988–2011 and followed until December 31, 
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2012. APL was diagnosed as histology code 9866 in the International Classification of 
Diseases for Oncology, third edition.16 Of 784 patients identified, 4 were excluded due to 
missing date of diagnosis and 8 due to unknown or Native American (small subgroup) race/
ethnicity. Our study included 772 patients.
Variables
The variables examined for association with APL outcomes were age at diagnosis, 
categorized as four groups based on progressive decrements in survival17 (0–9, 10–19, 20–
29 and 30–39 years); sex; era of diagnosis according to ATRA approval by the U.S. FDA 
(pre-ATRA era, 1988–1995; earlier ATRA era, 1996–2003; and later ATRA era, 2004–
2011); race/ethnicity (non–Hispanic white [white], non-Hispanic black [black], Hispanic, 
and Non-Hispanic Asian/Pacific Islander [Asian]); initial care at hospitals affiliated with 
National Cancer Institute (NCI)-designated cancer centers; type of health insurance at 
admission (routinely documented starting in 1996) (none, public, private or unknown/not 
otherwise specified); and neighborhood socioeconomic status (SES) based on block-level 
census data. Neighborhood SES quintiles based on statewide distribution have been utilized 
extensively in California.18
Information on hospital designation was from the initial reporting facility. There were no 
data on intensity of treatment or drugs used (conventional genotoxic chemotherapy, ATRA 
and/or arsenic).
Statistical analysis
We used univariable and multivariable logistic regression to investigate the association of 
the sociodemographic and clinical factors with 7- and 30-day mortality, through estimation 
of the odds ratios (ORs) and associated 95% confidence intervals (CIs). We analyzed 30-day 
mortality with and without patients who died within 7 days. We estimated overall survival 
(all-cause survival) at 1 and 5 years by using the Kaplan-Meier method, and compared 
differences in survival across strata for each variable using the log-rank test. We used 
univariable and multivariable Cox regression models to examine the association of 
sociodemographic and clinical factors with the risk of death, through estimation of the 
hazard ratios (HRs) and associated 95% CIs. Schoenfeld residuals were used to assess the 
proportional hazard assumptions. We tested for interactions between calendar periods, age 
groups, neighborhood SES and race/ethnicity. All statistical analyses we performed by using 
the Stata 13 software. A two-sided P<0.05 was considered statistically significant.
RESULTS
Approximately 16% of all AML cases in the registry were APL, most of which (79%) were 
diagnosed during the ATRA era (after 1995). According to death certificates, most patients 
died of leukemia (n=228, 90%); a much smaller percentage of patients died of other (n=17, 
7%) or unknown (n=7, 3%) causes. Fewer than 2% of patients died of complications of APL 
treatment, such as infection (n=2), renal dysfunction (n=1) or heart failure (n=1). Table 1 
summarizes patient characteristics.
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Early death
Among patients who experienced early death, median age at diagnosis was 29 years; 82 of 
these patients (11%) died within 7 days and 133 (17%) died within 30 days of diagnosis. 
Thirty-day mortality decreased significantly over the 3 eras from 26% in 1988–1995 (pre-
ATRA) to 16% in 1996–2003 (earlier ATRA era) to 14% in 2004–2011 (later ATRA era) 
(P=0.004, Table 1) (Figure 1). However, 7-day mortality showed no evidence of a 
significant decrease. In a multivariable analysis (Table 2), the odds of 30-day mortality 
differed significantly between 1988–1995 and later eras (P=0.001), but not between the 
1996–2003 and 2004–2011 eras. Hispanic patients had a risk of 30-day mortality 
approximately twice that of white patients. After 1995, type of health insurance was 
significantly associated with both 7-day and 30-day mortality; the risk of 30-day mortality 
was approximately 3 times as high in uninsured as in privately insured patients [OR=2.67 
(95% CI: 1.10–6.52)]. Early death was not found to differ significantly between patients 
with private vs. public insurance (P=0.243).
When patients with 7-day mortality (n=82) were excluded from analysis, 30-day mortality 
decreased from 15% during 1988–1995 to 8% during 1996–2003 and 3% during 2004–2011 
(P<0.0001; data not shown). There was no evidence of interactions between any variables.
Survival
During 0–25 years of follow-up (median in entire cohort, 4.4 years), 33% of patients 
(n=252) died. Five-year survival increased from 46.7% during 1988–1995 to 70.1% during 
1996–2003 and 77.3% during 2004–2011 (P<0.0001, Table 1). Based on the log-rank test, a 
lower survival estimate was significantly associated with earlier period of diagnosis, male 
sex, older age at diagnosis, and lack of health insurance (Table 1). In univariable analyses, 
survival was lower in Hispanic and black vs. white patients and uninsured vs. insured 
patients. In multivariable models, the 1988–1995 era, black/Hispanic race/ethnicity and lack 
of health insurance remained significantly associated with the hazard of death (Table 3). 
There was no evidence of a difference in HR between patients with private vs. public 
insurance (P=0.999). There was no evidence of violation of the Cox proportional hazard 
assumptions or of interactions between any variables.
When we excluded patients who died within 30 days of diagnosis in 1996–2011, 5-year 
survival increased from 77.8% (95% CI: 70.7%–83.3%) to 88.8% (95% CI: 82.4%–93.0%) 
among patients aged 0–19 years, and from 72.5% (95% CI: 67.8%–76.6%) to 86.3% (95% 
CI: 81.9%–89.7%) among patients aged 20–39 years (data not shown).
DISCUSSION
In our population-based study spanning 25 years, 30-day mortality decreased significantly 
after 1995, coinciding with the introduction of ATRA and guidelines recommending 
aggressive blood product support and intensive infection prophylaxis and treatment for 
suspected APL. Nevertheless, 30-day mortality remained higher than that observed in non-
APL subtypes of AML,19 and 7-day mortality did not improve over time. Our findings 
suggest that factors other than ATRA contributed to early death; these may include the 
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timing of diagnosis or chemotherapy, hospital availability of ATRA/arsenic during the 
critical 2–3 days after diagnosis, adequate blood products and infection prophylaxis and 
treatment. A recent study of randomly selected hospitals in the U.S. found that less than half 
had ATRA, and one of the main barriers to availability was the absence of ATRA on their 
formularies.20
Patients who suffered early death probably lacked early access to effective treatment and/or 
were too ill when admitted; ten patients in this study died on the day of diagnosis. The 
FDA’s approval of ATRA (and later, arsenic) may not have resulted in the wide or timely 
availability of these drugs across all California hospitals.
Moreover, despite the great effectiveness of ATRA and arsenic, treatment may cause severe 
complications that should be recognized and treated promptly, such as differentiation 
syndrome. Differentiation syndrome occurs in about 2%–31% of patients receiving 
induction therapy and can mimic other severe complications, such as pulmonary 
hemorrhage, renal dysfunction and heart failure.21 Because of the abrupt presentation and 
potential gravity of differentiation syndrome, preemptive use of corticosteroids has been 
proposed.22 The syndrome may be promoted by delaying chemotherapy after ATRA,23 and 
delaying ATRA itself for more than 2 days may increase the risk of fatal hemorrhage.24 
These findings confirm the importance of early diagnosis, rapid intensive treatment and 
adequate supportive care.
Importantly, we found that uninsured patients had a higher risk of early death and lower 
survival estimates than those with private and public insurance, suggesting lack of adequate 
access to care. Our results are consistent with a previous report of worse survival in 
uninsured vs. insured AYAs.25 Wider insurance coverage is likely to provide better 
outcomes for these patients. Additionally, early death was higher among Hispanic patients, 
and survival was lower among black and Hispanic patients, than those among white patients. 
Similar findings have been reported in children with acute lymphoblastic leukemia 
(ALL),26, 27 children with AML (excluding APL)28 and adults with AML (including 
APL).14 To provide effective and sustainable treatment to patients with APL – a severe but 
highly curable disease – efforts should also address the social contributors to health 
inequity,29 such as poverty, inadequate access to transportation, and lack of education 
resources.
In general, population-based studies,11, 12 such as ours, show a greater proportion of early 
death than do multi-institutional protocols. The differing findings may reflect the exclusion 
of patients who died during the first week or were too ill for chemotherapy in prior 
studies.30 In our study, when we excluded deaths within 7 days, we found 30-day mortality 
during the ATRA era to approximate that in clinical trials.10, 31 Similarly, when we excluded 
patients who died within 30 days of diagnosis, 5-year survival was close to that reported in 
multi-institutional trials in children and AYAs.32, 33 These observations suggest that 
selection bias may contribute to the differences in reported survival and early death between 
most clinical trials and population-based studies.
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Our study had several limitations. Hospital designation was limited to the location of initial 
care at the reporting facility, so it is possible that some patients diagnosed at one type of 
facility were subsequently treated at another. However, 92% of our patients received at least 
part of their treatment at this hospital, suggesting that our findings were not substantially 
influenced by this factor. We also lacked data on patients’ risk classification at diagnosis, 
laboratory data, and blood products administered. Although this information would likely 
have contributed additional important findings, disease outcomes such as early death and 
survival are of paramount concern. Survival is a measure of the cancer burden and the health 
system effectiveness and plays a key role in the development of health policies.34 Our large 
California APL cohort allowed us to compare early death and survival across treatment eras 
and investigate sociodemographic factors associated with outcome. To our knowledge, this 
is the first population-based study to investigate the association of race/ethnicity with early 
death and survival in children with APL and to consider the association of outcome with 
health insurance, hospital type, age, sex, treatment era and neighborhood SES. Further, 
unlike previous population-based studies,11, 12, 19 we were able to assess 7-day mortality.
In conclusion, our findings indicate a true reduction of 30-day mortality among children and 
AYAs with APL in California, suggesting adherence to modern therapeutic strategies. 
However, 7-day mortality remained high, suggesting that factors other than ATRA played a 
role in early death. We identified subgroups of patients vulnerable to early death and 
reduced survival, including the uninsured and Hispanic patients. Black patients also 
experienced worse survival. To improve outcomes among young patients with APL, efforts 
should focus on improving access to effective treatment, mainly among uninsured patients 
and those of Hispanic and Black race/ethnicity.
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Figure 1. Early death from acute promyelocytic leukemia in California, after diagnosis at age 0–
39 years
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A. Entire study period (1988–2011). B. Pre-ATRA era (1998–1995). C. Earlier ATRA era 
(1996–2003). D. Later ATRA era (2004–2011). Ten patients who died on the day of 
diagnosis were considered to have a survival time of 1 day.
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TABLE 2
Relation of sociodemographic and clinical factors to 30-day mortality
Odds ratio for 30-day mortality
Factor Unadjusted OR1
(95%CI)
(1988–2011)
Adjusted OR2
(95% CI)
(1988–2011)
Adjusted OR3
(95%CI)
(1996–2011)
Adjusted OR4
(95% CI)
(1996–2011)
Calendar period
1988–1995 (pre-ATRA) 2.18 (1.37–3.46) 3.01 (1.66–5.46) N/A N/A
1996–2003 (earlier ATRA era) 1.20 (0.77–1.87) 1.39 (0.80–2.43) 1.41(0.81–2.46) 1.30 (0.74–2.30)
2004–2011 (later ATRA era) 1 (base) 1 (base) 1 (base) 1 (base)
Sex
Male 1.42 (0.97–2.07) 1.21 (0.76–1.96) 1.22 (0.70–2.13) 1.18 (0.67–2.08)
Female 1 (base) 1 (base) 1 (base) 1 (base)
Age at diagnosis (years)
0–9 1 (base) 1 (base) 1 (base) 1 (base)
10–19 2.06 (0.69–6.22) 1.90 (0.54–6.74) 1.78 (0.40–7.95) 2.01 (0.44–9.18)
20–29 2.36 (0.80–6.95) 1.83 (0.52–6.42) 1.67 (0.38–7.38) 1.72 (0.38–7.78)
30–39 2.90 (1.01–8.35) 2.48 (0.73–8.45) 2.61 (0.61–11.1) 2.61 (0.60–11.4)
Race/ethnicity
White 1 (base) 1 (base) 1 (base) 1 (base)
Black 1.75 (0.77–3.97) 1.82 (0.63–5.20) 2.48 (0.72–8.51) 2.37 (0.68–8.31)
Hispanic 1.79 (1.14–2.79) 2.13 (1.16–3.89) 2.20 (1.04–4.63) 2.23 (1.01–4.92)
Asian 1.3 (0.65–2.61) 1.35 (0.56–3.26) 1.11 (0.36–3.51) 1.24 (0.39–3.87)
Neighborhood socioeconomic status (quintiles)
1. Lowest 20% 1.80 (0.92–3.52) 1.03 (0.44–2.44) 0/83 ((0.28–2.52) 0.87 (0.27–2.80)
2. 1.91 (0.96–3.79) 1.08 (0.46–2.53) 0.99 (0.33–2.92) 1.03 (0.33–3.20)
3. Middle 20% 1.38 (0.67–2.84) 0.93 (0.39–2.23) 0.88 (0.29–2.72) 0.93 (0.29–3.01)
4. 1.30 (0.61–2.77) 0.81 (0.32–2.02) 0.79 (0.25–2.53) 0.83 (0.25–2.72)
5. Highest 20% 1 (base) 1 (base) 1 (base) 1 (base)
Initial care at hospitals affiliated with NCI-designated cancer centers
Yes 1 (base) 1 (base) 1 (base) 1 (base)
No 1.53 (0.92–2.55) 1.07 (0.57–2.00) 1.30 (0.62–2.72) 1.19 (0.55–2.56)
Health insurance (limited to patients diagnosed in 1996–2011; n=609)
None 3.91 (2.01–7.62) N/A N/A 2.67 (1.10–6.52)
Public 0.66 (0.39–1.13) N/A N/A 0.66 (0.32–1.33)
Private 1 (base) N/A N/A 1 (base)
Unknown/NOS 0.40 (0.14–1.17) N/A N/A 0.22 (0.06–0.79)
Abbreviations: OR, odds ratio; CI, confidence interval; NCI, National Cancer Institute.
All multivariable comparisons were adjusted for chemotherapy (Y/N) and all variables in the table unless otherwise noted.
OR1: unadjusted model (1988–2011), OR2: adjusted model without insurance (1988–2011), OR3: adjusted model without insurance (1996–2011), 
OR4: adjusted model with insurance (1996–2011).
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